Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan

被引：0
|
作者：
H. Hagino
K. Tanaka
S. Silverman
M. McClung
S. R. Gandra
M. Charokopou
K. Adachi
B. Johnson
B. Stollenwerk
机构：
[1] Tottori University,Mary McKillop Center for Health Research
[2] Kobe Gakuin University,undefined
[3] Cedars Sinai,undefined
[4] Oregon Osteoporosis Center,undefined
[5] Australian Catholic University,undefined
[6] Amgen Inc.,undefined
[7] UCB BioPharma SPRL.,undefined
[8] Amgen K.K.,undefined
[9] Amgen Ltd.,undefined
[10] Amgen GmbH,undefined
来源：
Osteoporosis International | 2021年 / 32卷
关键词：
Bone mineral density; Cost effectiveness; Markov model; Osteoporosis; Romosozumab; Teriparatide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2011 / 2021
页数：10
相关论文
共 50 条
  • [1] Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan
    Hagino, H.
    Tanaka, K.
    Silverman, S.
    McClung, M.
    Gandra, S. R.
    Charokopou, M.
    Adachi, K.
    Johnson, B.
    Stollenwerk, B.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (10) : 2011 - 2021
  • [2] Cost-effectiveness of Romosozumab versus Teriparatide for Severe Postmenopausal Osteoporosis in Japan
    Hagino, Hiroshi
    Tanaka, Kiyoshi
    McClung, Michael
    Silverman, Stuart
    Gandra, Shravanthi
    Charokopou, Mata
    Adachi, Kenji
    Johnson, Benjamin
    Stollenwerk, Bjorn
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 256 - 256
  • [3] COST EFFECTIVENESS OF ROMOSOZUMAB FOLLOWED BY ALENDRONATE VERSUS TERIPARATIDE IN THE TREATMENT OF SEVERE OSTEOPOROSIS IN GREECE
    Golnas, P.
    Relakis, J.
    Kountouris, V
    Golna, C.
    Makras, P.
    Willems, D.
    Souliotis, K.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S57 - S57
  • [4] The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women With Osteoporosis
    Hartz, Martin C.
    Johannessen, Fabian B.
    Harslof, Torben
    Langdahl, Bente L.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [5] Osteoporosis: Romosozumab versus teriparatide
    Ummarino D.
    [J]. Nature Reviews Rheumatology, 2017, 13 (9) : 512 - 512
  • [6] Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis
    Ebina, Kosuke
    Etani, Yuki
    Noguchi, Takaaki
    Nakata, Ken
    Okada, Seiji
    [J]. JOURNAL OF BONE AND MINERAL METABOLISM, 2024,
  • [7] Postmenopausal osteoporosis with vertebral fracture: teriparatide vs romosozumab
    Torres, Manuel Munoz
    [J]. REVISTA DE OSTEOPOROSIS Y METABOLISMO MINERAL, 2023, 15 (02)
  • [8] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    E. Söreskog
    I. Lindberg
    J.A. Kanis
    K.E. Åkesson
    D. Willems
    M. Lorentzon
    O. Ström
    P. Berling
    F. Borgström
    [J]. Osteoporosis International, 2021, 32 : 585 - 594
  • [9] Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
    Soreskog, E.
    Lindberg, I.
    Kanis, J. A.
    Akesson, K. E.
    Willems, D.
    Lorentzon, M.
    Strom, O.
    Berling, P.
    Borgstrom, F.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2021, 32 (03) : 585 - 594
  • [10] Romosozumab versus teriparatide in premenopausal women with idiopathic osteoporosis
    Lee, Seunghyun
    Shin, Sungjae
    Hong, Namki
    Lim, Jung Soo
    Rhee, Yumie
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 166 - 166
12345